Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism

Journal of the American Medical Directors Association

Volumn 5, Issue 2, 2004, Pages 129-132

  Smith, David A ^a   Beier, Manju T ^a  

^a Geriatric Consultants of Central Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEHYDRATION; DEMENTIA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; GYNECOMASTIA; HEMOCONCENTRATION; HUMAN; HYPERPROLACTINEMIA; HYPOTHESIS; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NURSING HOME; OCCLUSIVE CEREBROVASCULAR DISEASE; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PRACTICE GUIDELINE; PSYCHOSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 1642408640     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70069-9     Document Type: Editorial

References (16)

1. Smith DA. Dementia. In: Rakel RE, ed. Textbook of Family Practice, 6th ed. Philadelphia: WB Saunders Co; 2002:1505-1512.
2. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-136.
3. Health Care Financing Administration. Medicare and Medicaid: Requirements for Long-Term Care Facilities. Final regulations. Federal Register 1991;56:48865-48921.
4. Coccaro EF, Kramer E, Zemishlany A, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990;147:1640-1645.
5. Maletta GJ. Pharmacologic treatment and management of the aggressive demented patient. Psychiatric Annals 1990;20:446-455.
6. Tariot PN, Ryan JM, Porsteinsson AP, et al. Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clin Geriatr Med 2001;17: 359-376.
7. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review). Neurology 2001;56: 1154-1166.
8. Important Drug Safety Information: RISPERDAL (risperidone) and Cerebrovascular Adverse Events in Placebo-controlled Dementia Trails-Janssen-Ortho Inc. Available at: hhtp://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/risperdal e.html. Accessed June 20, 2003.
9. Katz IR, Dilip VJ, Jacobo EM, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115.
10. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143.
11. DeDeyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
12. Resperdal Product Information. Titusville, NJ: Janssen Pharmaceutica Products; March 2003.
13. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: Impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-1391.
14. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: A case-control study. Lancet 2000; 356:1219-1223.
15. Kortepeter C, Chen M, Knudsen JF, et al. Clozapine and venous thromboembolism. Am J Psychiatry 2002;159:876-877.
16. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patient with Alsheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-976.